Skip to Main Content

Recombinant, animal-origin-free biomanufacturing

InVitria takes animal-derived components out of biomanufacturing.

We manufacture recombinant, animal-origin-free proteins and chemically defined media for cell culture, biomanufacturing, and final formulation, from gene to final product.

19
Years removing animal-derived components
>1,000
Active customers worldwide
>40
Products on the market using InVitria’s components
7
Approved therapeutics using InVitria proteins
>40
Countries served
Wide view of an operator running a bioprocessing system

Our Mission

AOF, from start to finish.

InVitria exists to remove animal-derived components from the materials used to make medicines. The recombinant proteins and chemically defined media we manufacture are designed to carry a process from gene to final product without a single input collected from blood, serum, or tissue. That is the entire purpose of the company, not one capability.

Validation and partnership

The standards other serious organizations already apply.

Partner: Merck

InVitria’s recombinant human serum albumin is an excipient in ERVEBO, the first FDA- and EMA-approved vaccine to include recombinant human serum albumin in final formulation.


Distribution partner

Partner: Evonik

Evonik, a specialty chemicals manufacturer reporting €14.1 billion in FY2025 revenue, partnered with InVitria to expand access to animal-free albumin.


Co-development partner

Partner: Cellevate

InVitria and Cellevate AB are collaborating to pair Cellevate’s Cellevat3d nanofiber microcarrier with InVitria recombinant proteins for animal-origin-free viral vaccine manufacturing.

Scientist reviewing protein analysis results on a monitor

Manufacturing and quality

Built to a documented quality system.

Certified facility
Junction City, Kansas, ISO 9001:2015 certified and cGMP compliant, made in the USA.
Documented quality system
A quality management system a QA reviewer can audit.
Lot-specific Certificate of Analysis
Released with every batch, with the specifics that go into a filing.

Questions, answered

The questions buyers ask first.

A starting point for evaluation. The full list goes deeper on quality and regulatory.

Talk to the team

Talk through your application with our team.

The next step is a conversation about your specific cell line, modality, and stage.